Patient Corner

Anatomical Illustrations

More

Last reference updates

  • Sep 29, 2017 - MedWatch Drug Updates

FDA update: Type III endoleaks associated with the use of endovascular graft systems

FDA evaluates recent information regarding Type IIIa and IIIb endoleaks with the use of endovascular graft systems indicated for a endovascular aneurysm repair (EVAR)

  • Sep 28, 2017 - MedWatch Drug Updates

FDA update: High risk of mortality and neurological adverse events when using SynCardia's TAH-t C2 Driver System

Increased risk of mortality and neurological adverse events in patients using TSynCardia's TAH-t C2 Driver System.

  • Sep 28, 2017 - MedWatch Drug Updates

Class I Recall of Bridge Occlusion Balloon Catheter Model 590-001 by Spectranetics: Blocked guidewire lumen

Spectranetics has recalled Bridge Occlusion Balloon Catheter due to blockage of guidewire lumen which may results in serious adverse events.

  • Sep 18, 2017 - FDA Drug Updates

FDA approved Aliqopa (copanlisib) for the treatment of relapsed follicular lymphoma

Aliqopa (copanlisib) is approved for the treatment of relapsed follicular lymphoma in adults who have received prior systemic therapies

  • Sep 18, 2017 - FDA Drug Updates

FDA approved Mvasi (bevacizumab-awwb) for the treatment of cancer

Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) is approved for the treatment of multiple types of cancer.

  • Oct 9, 2017 - MedWatch Drug Updates

Recall of Intralipid 20 % IV Fat Emulsion by Baxter: One lot of product exposed to subfreezing temperature

Baxter International issued a voluntary recall of Intralipid 20 % IV Fat Emulsion as it has exposed to subfreezing temperature.

  • Oct 5, 2017 - MedWatch Drug Updates

Case of HORV reported after intraocular Inj of a compounded triamcinolone, moxifloxacin, vancomycin

FDA received reports of hemorrhagic occlusive retinal vasculitis post administration of Inj of compounded triamcinolone, moxifloxacin, and vancomycin.

  • Sep 7, 2017 - MedWatch Drug Updates

FDA recommends separate dosing for Kayexalate (sodium polystyrene sulfonate) from all other oral drugs

Kayexalate (sodium polystyrene sulfonate) binds to many commonly prescribed oral medicines and decreases its absorption and effectiveness.

  • Sep 7, 2017 - MedWatch Drug Updates

Class I Recall of Intra-Aortic Balloon Pump by Datascope/MAQUET- False blood detection alarm and ingress of fluid into the pump

Intra-Aortic Balloon Pump device failure may result in serious adverse health effect or death.

  • Oct 4, 2017 - MedWatch Drug Updates

FDA alert- Not to use infant sleep positioners as it can cause suffocation

FDA warning against the use of infant sleep positioners due to risk of suffocation.